78 related articles for article (PubMed ID: 22891675)
21. Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.
Adler M; Bryant J; Buckman B; Islam I; Larsen B; Finster S; Kent L; May K; Mohan R; Yuan S; Whitlow M
Biochemistry; 2005 Jul; 44(26):9339-47. PubMed ID: 15982000
[TBL] [Abstract][Full Text] [Related]
22. Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor.
Owen DR; Bull DJ; Bunnage ME; Glossop MS; Maguire RJ; Strang RS
Bioorg Med Chem Lett; 2010 Jan; 20(1):92-6. PubMed ID: 19954973
[TBL] [Abstract][Full Text] [Related]
23. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa).
Noguchi K; Edo N; Miyoshi N; Isobe A; Watanabe A; Ito Y; Morishima Y; Yamaguchi K
Thromb Res; 2018 Aug; 168():96-101. PubMed ID: 29957475
[TBL] [Abstract][Full Text] [Related]
25. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
26. [The TAFI system. The new role of fibrinolysis].
Dempfle CE
Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
[TBL] [Abstract][Full Text] [Related]
27. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation.
Valnickova Z; Christensen T; Skottrup P; Thøgersen IB; Højrup P; Enghild JJ
Biochemistry; 2006 Feb; 45(5):1525-35. PubMed ID: 16445295
[TBL] [Abstract][Full Text] [Related]
28. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
30. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
Nesheim M; Wang W; Boffa M; Nagashima M; Morser J; Bajzar L
Thromb Haemost; 1997 Jul; 78(1):386-91. PubMed ID: 9198184
[TBL] [Abstract][Full Text] [Related]
31. Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).
Schreuder H; Liesum A; Lönze P; Stump H; Hoffmann H; Schiell M; Kurz M; Toti L; Bauer A; Kallus C; Klemke-Jahn C; Czech J; Kramer D; Enke H; Niedermeyer THJ; Morrison V; Kumar V; Brönstrup M
Sci Rep; 2016 Sep; 6():32958. PubMed ID: 27604544
[TBL] [Abstract][Full Text] [Related]
32. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Ito Y; Noguchi K; Morishima Y; Yamaguchi K
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):314-321. PubMed ID: 29538006
[TBL] [Abstract][Full Text] [Related]
33. Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.
Halland N; Brönstrup M; Czech J; Czechtizky W; Evers A; Follmann M; Kohlmann M; Schiell M; Kurz M; Schreuder HA; Kallus C
J Med Chem; 2015 Jun; 58(11):4839-44. PubMed ID: 25990761
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor.
Develter J; Dewilde M; Gils A; Declerck PJ
Thromb Haemost; 2009 Jul; 102(1):69-75. PubMed ID: 19572070
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives.
Do YH; Gifford-Moore DS; Beight DW; Rathnachalam R; Klimkowski VJ; Warshawsky AM; Lu D
Thromb Res; 2005; 116(3):265-71. PubMed ID: 15935836
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B.
Suzuki K; Muto Y; Fushihara K; Kanemoto K; Iida H; Sato E; Kikuchi C; Matsushima T; Kato E; Nomoto M; Yoshioka S; Ishii H
J Pharmacol Exp Ther; 2004 May; 309(2):607-15. PubMed ID: 14762098
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).
Polla MO; Tottie L; Nordén C; Linschoten M; Müsil D; Trumpp-Kallmeyer S; Aukrust IR; Ringom R; Holm KH; Neset SM; Sandberg M; Thurmond J; Yu P; Hategan G; Anderson H
Bioorg Med Chem; 2004 Mar; 12(5):1151-75. PubMed ID: 14980627
[TBL] [Abstract][Full Text] [Related]
38. [TAFI--thrombin activated fibrinolysis inhibitor ].
Hryszko T; Małyszko J; Brzósko S; Myśliwiec M
Przegl Lek; 2001; 58(3):136-8. PubMed ID: 11475860
[TBL] [Abstract][Full Text] [Related]
39. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization.
Wang YX; Zhao L; Nagashima M; Vincelette J; Sukovich D; Li W; Subramanyam B; Yuan S; Emayan K; Islam I; Hrvatin P; Bryant J; Light DR; Vergona R; Morser J; Buckman BO
Thromb Haemost; 2007 Jan; 97(1):45-53. PubMed ID: 17200770
[TBL] [Abstract][Full Text] [Related]
40. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
